---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-055490"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-08-11T11:14:05+00:00"
generated_at: "2026-08-11T11:15:13.007304+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# C4T Q2 2026 net loss $23.6M ($0.18/sh), cash $300.4M, cemsidomide trials on track

## Summary
- Q2 2026 revenue $6.6M (vs $6.5M YoY); net loss $23.6M vs $26.0M; EPS -$0.18 vs -$0.37.
- Cash, equivalents & securities $300.4M at Jun 30, 2026; funded to end of 2028.
- Phase 2 MOMENTUM enrollment on track for Q1 2027; ORR data expected H2 2027.
- Roche DAC collaboration: $20M upfront paid May 2026; new Phase 1b trial with daratumumab/carfilzomib to start H1 2027.
- EHA 2026 data: ORR 40% at 75 µg and 53% at 100 µg doses in late-line MM; 2 MRD-negative patients.

## SEC filing metadata
- accession: 0001628280-26-055490
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-08-11T11:14:05+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/0001628280-26-055490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-055490
- JSON: https://secwatch.observer/filing/0001628280-26-055490.json
- Plain text: https://secwatch.observer/filing/0001628280-26-055490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.